Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elizabeth Nally
Observed name:
E. Nally
Institutions:
Queen Mary University of London,
Barts Health NHS Trust,
The Royal Free Hospital,
Barts Cancer Institute
Observed institutions:
St Bartholomew's Hospital,
Queen Mary University of London,
Barts Health NHS Trust,
The Royal Free Hospital,
Barts Cancer Institute
ORCID:
0009-0006-0665-5210
Observed ORCID:
0009-0006-0665-5210
OpenAlex ID:
A5063807647
Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge
2024
·
Elizabeth Nally
, Matthew Young
, et al.
·
Cancer Management and Research
·
25
PDF
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
2024
·
Matthew Young
, Jose C. Tapia
, et al.
·
Clinical Genitourinary Cancer
·
17
PDF
Established and emerging biomarkers approaches in urothelial carcinoma
2025
·
Sara Coca Membribes
, Elizabeth Nally
, et al.
·
Expert Review of Anticancer Therapy
·
10
Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
2024
·
Matthew Nicholas Young
, Bernadett Szabados
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
2024
·
Elizabeth Nally
, Matthew Young
, et al.
·
European Urology Focus
·
6
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
2025
·
Cristiane D. Bergerot
, David Cella
, et al.
·
European Urology Oncology
·
5
Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study.
2024
·
Cristiane Decat Bergerot
, Daniela V. Castro
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
2026
·
Elizabeth Nally
, Veda Kudva
, et al.
·
Journal of Clinical Oncology
·
2
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
2025
·
Cristiane Decat Bergerot
, Paulo Gustavo Bergerot
, et al.
·
Journal of Clinical Oncology
·
2
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
2024
·
Karl Semaan
, Rashad Nawfal
, et al.
·
The Lancet Oncology
·
2
Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab.
2024
·
Francesca Jackson-Spence
, Vishwani Chauhan
, et al.
·
Journal of Clinical Oncology
·
2
Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: Results from a UK Tertiary Renal Cancer Network
2026
·
Federica Sordelli
, Giuseppe Basile
, et al.
·
European Urology Oncology
·
1
HER1–HER4 expression and co-expression in advanced urothelial carcinoma
2026
·
S. Coca Membribes
, D.M. Berney
, et al.
·
ESMO Open
·
1
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis
2026
·
Elizabeth Nally
, Agne Jovaisaite
, et al.
·
Cancers
·
1
PDF
KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.
2026
·
Sara Coca Membribes
, Francesca Jackson-Spence
, et al.
·
Journal of Clinical Oncology
·
1
Is it time to reassess standard toxicity and patient-reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?
2026
·
E. Nally
, J. Lyon
, et al.
·
Annals of Oncology
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy
2026
·
Francesca Jackson‐Spence
, Domiziana Aspden
, et al.
·
Cancer Medicine
Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial.
2026
·
Syed A. Hussain
, Iciar García Carbonero
, et al.
·
Journal of Clinical Oncology
Patient and trial design factors influencing participation in prospective bladder and kidney cancer clinical trials.
2026
·
Catherine Graham
, Sara Coca Membribes
, et al.
·
Journal of Clinical Oncology
PDF
P0396 Adjuvant pembrolizumab for surgically treated clear cell renal cell carcinoma: The first experience of high-volume referral centers
2026
·
F. Sordelli
, G. Basile
, et al.
·
European Urology
165P Adjuvant pembrolizumab for early-stage renal cell carcinoma: A real-world experience from two UK tertiary oncology centers
2025
·
E. Nally
, F. Sordelli
, et al.
·
Immuno-Oncology Technology
PDF
11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis
2025
·
Koral Shah
, Paulo Gustavo Bergerot
, et al.
·
The Oncologist
PDF
Perioperative durvalumab for muscle invasive bladder cancer: the start of a new chapter
2025
·
Elizabeth Nally
, Thomas Powles
·
Future Oncology
PDF
Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer.
2025
·
Elizabeth Nally
, Gemma Ainsworth
, et al.
·
Journal of Clinical Oncology
Systemic therapy clinical trial participation in patients with bladder and kidney cancers.
2025
·
Connor Wells
, Elizabeth Nally
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
28
Citation count:
85
H-index:
5
I10-index:
3
Year
Topic
Type